Voloridge Investment Management LLC Has $40.01 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Voloridge Investment Management LLC lowered its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 12.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 351,095 shares of the company's stock after selling 49,211 shares during the period. Voloridge Investment Management LLC owned approximately 0.15% of BioNTech worth $40,007,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. FMR LLC increased its holdings in shares of BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of BioNTech during the 4th quarter valued at $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of BioNTech by 632.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after acquiring an additional 433,388 shares in the last quarter. Capital International Investors grew its holdings in shares of BioNTech by 38.6% during the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after acquiring an additional 394,434 shares in the last quarter. Finally, abrdn plc increased its stake in shares of BioNTech by 70.7% in the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock worth $43,947,000 after acquiring an additional 159,676 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BNTX shares. Citigroup reiterated a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Canaccord Genuity Group reissued a "buy" rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. JPMorgan Chase & Co. reduced their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday. Morgan Stanley cut their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $134.00 price target on shares of BioNTech in a report on Thursday. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and an average price target of $141.73.

BioNTech Stock Performance

BNTX stock traded down $0.39 on Monday, reaching $98.68. 598,407 shares of the company were exchanged, compared to its average volume of 920,126. The firm has a market capitalization of $23.72 billion, a PE ratio of -46.99 and a beta of 1.35. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The stock's fifty day moving average price is $97.40 and its 200 day moving average price is $108.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.90 EPS. On average, research analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.